Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
07 07 2021
Historique:
received: 16 09 2020
accepted: 08 04 2021
pubmed: 12 4 2021
medline: 24 7 2021
entrez: 11 4 2021
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of 8 February 2020 and causing more than 2.3 million deaths according to the World Health Organization (WHO). Not only affecting the lungs but also provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Hence a significant proportion of infected patients develop cardiac events, such as arrhythmias and heart failure. Patients with cardiovascular comorbidities are at highest risk of cardiac death. To face the pandemic and limit its burden, health authorities have launched several fast-track calls for research projects aiming to develop rapid strategies to combat the disease, as well as longer-term projects to prepare for the future. Biomarkers have the possibility to aid in clinical decision-making and tailoring healthcare in order to improve patient quality of life. The biomarker potential of circulating RNAs has been recognized in several disease conditions, including cardiovascular disease. RNA biomarkers may be useful in the current COVID-19 situation. The discovery, validation, and marketing of novel biomarkers, including RNA biomarkers, require multi-centre studies by large and interdisciplinary collaborative networks, involving both the academia and the industry. Here, members of the EU-CardioRNA COST Action CA17129 summarize the current knowledge about the strain that COVID-19 places on the cardiovascular system and discuss how RNA biomarkers can aid to limit this burden. They present the benefits and challenges of the discovery of novel RNA biomarkers, the need for networking efforts, and the added value of artificial intelligence to achieve reliable advances.

Identifiants

pubmed: 33839767
pii: 6220322
doi: 10.1093/cvr/cvab094
pmc: PMC8083253
doi:

Substances chimiques

Biomarkers 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1823-1840

Subventions

Organisme : British Heart Foundation
ID : RG/20/9/35101
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/15/1/31199
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Eur J Heart Fail. 2019 Jun;21(6):715-731
pubmed: 31222929
Comput Biol Med. 2018 Apr 1;95:99-106
pubmed: 29482119
Am J Med. 2020 Sep;133(9):e451-e454
pubmed: 32320696
Heart. 2020 Aug;106(15):1142-1147
pubmed: 32461330
Eur J Clin Invest. 2020 Jul;50(7):e13270
pubmed: 32415992
Front Cell Infect Microbiol. 2020 Oct 29;10:586592
pubmed: 33194826
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Cardiovasc Res. 2020 Dec 1;116(14):2197-2206
pubmed: 33063089
Nat Genet. 2012 Jan 27;44(2):121-6
pubmed: 22281772
BMC Genomics. 2019 Jun 3;20(1):446
pubmed: 31159762
Sci Adv. 2020 Dec 9;6(50):
pubmed: 33187979
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391
pubmed: 32169400
Sci Rep. 2017 Jul 19;7(1):5913
pubmed: 28724941
PLoS Genet. 2013;9(8):e1003657
pubmed: 23950726
Infect Genet Evol. 2020 Nov;85:104422
pubmed: 32544615
PLoS One. 2020 Nov 3;15(11):e0241742
pubmed: 33141836
SN Compr Clin Med. 2020;2(10):1761-1766
pubmed: 32864572
Eur Heart J. 2020 May 14;41(19):1852-1853
pubmed: 32297932
BMC Genomics. 2018 Jul 13;19(1):531
pubmed: 30001700
Cell Discov. 2020 Feb 24;6:11
pubmed: 32133153
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Eur Heart J. 2020 Sep 14;41(35):3296-3298
pubmed: 33033839
Eur Heart J. 2020 May 14;41(19):1860
pubmed: 32285915
Toxicology. 2014 Oct 3;324:147-57
pubmed: 24880025
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Bioinformatics. 2018 Jul 1;34(13):2185-2194
pubmed: 29462250
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
Front Immunol. 2020 Oct 09;11:590870
pubmed: 33163005
Viral Immunol. 2021 Jun;34(5):336-341
pubmed: 33202195
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Nucleic Acids Res. 2016 Jul 27;44(13):5995-6018
pubmed: 27317696
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
N Engl J Med. 2020 Jun 18;382(25):2478-2480
pubmed: 32302081
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
J Cell Physiol. 2020 Dec;235(12):9884-9894
pubmed: 32510598
J Infect. 2020 Sep;81(3):e99-e100
pubmed: 32416124
Cardiol Ther. 2020 Dec;9(2):293-305
pubmed: 32535752
JAMA Cardiol. 2020 Jul 1;5(7):751-753
pubmed: 32219362
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154
pubmed: 32602883
Eur J Heart Fail. 2021 Mar;23(3):468-475
pubmed: 33421274
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D112-5
pubmed: 15608158
Cardiovasc Res. 2020 Dec 1;116(14):2207-2215
pubmed: 32966582
SAR QSAR Environ Res. 2005 Dec;16(6):517-29
pubmed: 16428129
Pharmacol Rev. 2014 Oct;66(4):1142-74
pubmed: 25261534
PLoS One. 2020 Aug 21;15(8):e0238160
pubmed: 32822430
PLoS One. 2013 Jun 07;8(6):e64795
pubmed: 23762257
Infect Genet Evol. 2020 Nov;85:104417
pubmed: 32526370
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Nucleic Acids Res. 2017 May 5;45(8):e57
pubmed: 28053114
ESC Heart Fail. 2020 Oct;7(5):2440-2447
pubmed: 32529795
J Am Coll Cardiol. 2020 Nov 17;76(20):2334-2348
pubmed: 33129663
J Virol. 2009 Apr;83(7):3039-48
pubmed: 19004938
Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221
pubmed: 32372695
Scand J Clin Lab Invest. 2020 Oct;80(6):441-447
pubmed: 32449374
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Cardiovasc Res. 2017 Jun 1;113(7):725-736
pubmed: 28460026
CMAJ. 2020 Jul 13;192(28):E791-E798
pubmed: 32586839
Genes Dis. 2020 Dec;7(4):542-550
pubmed: 32363223
PLoS One. 2011;6(9):e24145
pubmed: 21909417
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Methods. 2013 Jan;59(1):S1-6
pubmed: 23036329
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32423125
Eur Heart J. 2020 May 14;41(19):1796-1797
pubmed: 32282026
J Am Med Inform Assoc. 2010 Mar-Apr;17(2):124-30
pubmed: 20190053
Nat Struct Mol Biol. 2009 Sep;16(9):961-6
pubmed: 19668211
NAR Genom Bioinform. 2020 Feb 12;2(1):lqaa008
pubmed: 33575555
Methods. 2016 Dec 1;111:21-31
pubmed: 27592382
Int J Infect Dis. 2020 Jun;95:304-307
pubmed: 32344011
AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:6-8
pubmed: 24303286
Int J Mol Sci. 2020 May 25;21(10):
pubmed: 32466222
Sci Rep. 2019 Nov 26;9(1):17574
pubmed: 31772251
Brain Behav Immun. 2020 Jul;87:18-22
pubmed: 32240762
Prog Cardiovasc Dis. 2020 Jul - Aug;63(4):518-524
pubmed: 32305557
Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7
pubmed: 32579880
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026
pubmed: 32936273
J Am Coll Cardiol. 2020 Sep 8;76(10):1244-1258
pubmed: 32652195
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Crit Care. 2020 Jul 28;24(1):468
pubmed: 32723362
Bioinformatics. 2017 Jul 15;33(14):2229-2231
pubmed: 28334291
Int J Infect Dis. 2020 Jul;96:467-474
pubmed: 32425643
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Oncotarget. 2017 Feb 28;8(9):15252-15266
pubmed: 28146434
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
PLoS One. 2012;7(7):e41561
pubmed: 22859996
Sci Rep. 2016 Nov 16;6:37252
pubmed: 27849031
PLoS One. 2020 Sep 17;15(9):e0239235
pubmed: 32941548
Circulation. 2020 Jan 28;141(4):313-328
pubmed: 31986093
Cardiovasc Res. 2018 Jan 1;114(1):19-34
pubmed: 29106545
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Pharm Pharm Sci. 2020;23:396-405
pubmed: 33086028
Clin Transl Immunology. 2020 Oct 14;9(10):e1192
pubmed: 33082954
Cardiovasc Res. 2017 May 1;113(6):564-585
pubmed: 28453734
Eur Heart J. 2020 May 14;41(19):1807-1809
pubmed: 32383758
Genome Biol. 2018 Sep 3;19(1):105
pubmed: 30173660
Sci Rep. 2020 Apr 29;10(1):7211
pubmed: 32350368
J Mol Cell Cardiol. 2020 Jul;144:47-53
pubmed: 32360703
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
Sci Rep. 2016 Sep 13;6:32651
pubmed: 27623086
Biomark Res. 2020 Aug 31;8:37
pubmed: 32879731
Cell Metab. 2020 Aug 4;32(2):188-202.e5
pubmed: 32610096
J Clin Lab Anal. 2020 Oct;34(10):e23590
pubmed: 32960473
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748

Auteurs

Lina Badimon (L)

Cardiovascular Science Program-ICCC, IR-Hospital de la Santa Creu i Santa Pau, Ciber CV, Autonomous University of Barcelona, Barcelona, Spain.

Emma L Robinson (EL)

Department of Cardiology, School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Amela Jusic (A)

Cardiovascular Research Unit, Department of Population Health, Luxembourg Institute of Health, 1A-B rue Edison, L-1445 Strassen, Luxembourg.

Irina Carpusca (I)

Cardiovascular Research Unit, Department of Population Health, Luxembourg Institute of Health, 1A-B rue Edison, L-1445 Strassen, Luxembourg.

Leon J deWindt (LJ)

Department of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.

Costanza Emanueli (C)

National Heart & Lung Institute, Faculty of Medicine, Imperial College London, London, UK.

Péter Ferdinandy (P)

Cardiometabolic Research Group and MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest,Hungary.
Pharmahungary Group, Szeged, Hungary.

Wei Gu (W)

Luxembourg Center for Systems Biomedicine, University of Luxembourg, Esch sur Alzette, Luxembourg.

Mariann Gyöngyösi (M)

Department of Cardiology, Medical University of Vienna, Vienna, Austria.

Matthias Hackl (M)

TAmiRNA GmbH, Vienna, Austria.

Kanita Karaduzovic-Hadziabdic (K)

Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

Mitja Lustrek (M)

Department of Intelligent Systems, Jozef Stefan Institute, Ljubljana, Slovenia.

Fabio Martelli (F)

Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, San Donato Milanese, Milan 20097, Italy.

Eric Nham (E)

University of Zagreb School of Medicine, Zagreb, Croatia.

Ines Potočnjak (I)

Institute for Clinical Medical Research and Education, University Hospital Centre Sisters of Charity, Zagreb, Croatia.

Venkata Satagopam (V)

Luxembourg Center for Systems Biomedicine, University of Luxembourg, Esch sur Alzette, Luxembourg.

Reinhard Schneider (R)

Luxembourg Center for Systems Biomedicine, University of Luxembourg, Esch sur Alzette, Luxembourg.

Thomas Thum (T)

Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover,Germany.
REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.

Yvan Devaux (Y)

Cardiovascular Research Unit, Department of Population Health, Luxembourg Institute of Health, 1A-B rue Edison, L-1445 Strassen, Luxembourg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH